Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): Multicenter study of patients treated with RT inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 6, 2001, Pages 1836-1842

  Masquelier, Bernard ^b   Race, Esther ^a   Tamalet, Catherine ^c   Descamps, Diane ^c   Izopet, Jacques ^c   Buffet Janvresse, Claudine ^c   Ruffault, Annick ^c   Mohammed, Ali Si ^c   Cottalorda, Jacqueline ^c   Schmuck, Anne ^c   Calvez, Vincent ^c   Dam, Elisabeth ^a   Fleury, Hervé ^c   Brun Vézinet, Françoise ^c  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL PELLEGRIN   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; DRUG EFFICACY; GENE DELETION; GENE INSERTION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE;

DRUG RESISTANCE, MICROBIAL; EPIDEMIOLOGY, MOLECULAR; GENOME, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; PHENOTYPE; PREVALENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; VARIATION (GENETICS);

EID: 0034999828     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.6.1836-1842.2001     Document Type: Article

References (31)

1. Balotta, C., M. Violin, L. Monno, P. Bagnarelli, C. Riva, G. Facchi, A. Berlusconi, M. Lippi, S. Rusconi, M. Clementi, M. Galli, G. Angarano, and M. Moroni. 2000. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure. J. Acquir. Immune Defic. Syndr. 24:232-240.
2. Boucher, C. A. B., E. O'Sullivan, J. W. Mulder, C. Ramautarsing, P. Kellam, G. Darby, J. M. A. Lange, J. Goudsmit, and B. A. Larder. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165:105-110.
3. Charneau, P., G. Mirambeau, P. Roux, S. Paulous, H. Bue, and F. Clavel. 1994. HIV-1 reverse transcription: a termination step at the centre of the genome. J. Mol. Biol. 241:651-662.
4. Chou, T.-C. 1991. The median-effect principle and the combination index for quantitation of synergism and antagonism. P. 61-102. In T.-C. Chou and J. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, New York, N.Y.
5. Clavel, F., M. D. Hoggan, R. L. Willey, K. Strebel, M. A. Martin, and R. Repaske. 1989. Genetic recombination of human immunodeficiency virus. J. Virol. 63:1455-1459.
6. Colonno, R. J., Y. T. Wachtfogel, K. Hertogs, and B. A. Larder. 2000. Frequency of stavudine and didanosine resistance among a large number of randomly selected HIV-1 isolates. Antivir. Ther. 5:85.
7. De Antoni, A., J. Foli, J. Lisziewicz, and F. Lori. 1997. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea conihination therapy. J. Infect. Dis. 176:899-903.
8. de Jong, J. J., J. Goudsmit, V. V. Lukashov, M. E. Hillebrand, E. Baan, R. Huismans, S. A. Danner, J. H. Ten Veen, F. De Wolf, and S. Jurrians. 1999. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 13:75-80.
9. Descamps, D., D. Costagliola, G. Glaude, C. Buffet-Janvresse, V. Calvez, G. Collin, J. Cottalorda, F. Ferchal, M. Harzic, J. Izopet, B. Masquelier, A. Ruffault, A. Schmuck, C. Tamalet, A. Yvon, F. Brun-Vézinet, and the French ANRS Antiretroviral Resistance Study Group. 1999. Prevalence of resistance mutations in anliretroviral-naive patients: French National Study. Antivir. Ther. 4(S1):87.
10. Hertogs, K., S. Bloor, V. de Vroey, C. Van Den Eynde, P. Dehertogh, A. Van Cauwenberge, M. Stürmer, T. Alcorn, S. Wegner, M. Van Houtte, V. Miller, and B. A. Larder. 2000. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob. Agents Chemother. 44:568-573.
11. Hirsch, M. S., F. Brun-Vézinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clolet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug testing in adull HIV-1 infection. JAMA 283:2417-2426.
12. Iversen, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
13. Jung, M., H. Agut, D. Candotti, D. Ingrand, C. Katlama, and J. M. Huraux. 1992. Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 5:359-364.
14. Kellam, P., C. A. B. Boucher, and B. A. Larder. 1992. A novel fifth mutation in HIV-1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 80:1934-1938.
15. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
16. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
17. Larder, B. A., S. Bloor, S. D. Kemp, K. Hertogs, R. L. Desmet, V. Miller, M. Sturmer, S. Staszewski, J. Ren, D. K. Stammers, D. I. Stuart, and R. Pauwels. 1999 A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob. Agents Chemother. 43:1961-1967.
18. Masquelier, B., I. Pellegrin, A. Ruffault, J.-M. Ragnaud, P. Morlat, C. Michelet, F. Doignon, N. Biteau, and H. J. A. Fleury. 1995. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:330-334.
19. Masquelier, B., D. Descamps, I. Carriere, F. Ferchal, G. Collin, M. Denayrolles, A. Ruffault, B. Chanzy, J. Izopet, C. Buffet-Janvresse, M. P. Schmitt, E. Race, H. J. A. Fleury, J. P. Aboulker, P. Yeni, and F. Brun-Vézinet. 1999. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the Delta lamivudine roll-over study. Antivir. Ther. 4:7-18.
20. Race, E., E. Dam, V. Obry, S. Paulous, and F. Clavel. 1999. Analysis of human immunodeficiency virus type 1 cross-resistance to protease inhibitors in patients failing on combination therapies using a rapid single-cycle recombinant virus assay. AIDS 13:2061-2068.
21. Rakik, A., M. Ait-Khaled, P. Griffin, D. A. Thomas, M. Tisdale, and J. P. Kleim for the abacavir CNA2007 International Study Group. 1999. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. J. Aquir. Immune Defic. Syndr. 22:139-145.
22. Ross, L., M. Johnson, N. Graham, M. Shaefer and M. St. Clair. 1999. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1 infected individuals, including those without prior or concurrent zidovudine therapy. J. Hum. Virol. 2:290-295.
23. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antivir. News 8:65-91.
24. Shirasaka, T., M. F. Kavlick, T. Ueno, W.-Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, et al. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
25. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV reverse transcriptase. Science 253:1537-1559.
26. Tamalet, C., J. Izopet, N. Koch, J. Fantini, and N. Yahi. 1998. Stable rearrangements of the β3-β4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy. AIDS 12:F161-F166.
27. Tamalet, C., N. Yahi, C. Tourres, P. Colson, A. M. Quinson, I. Poizot-Martin, C. Dhiver, and J. Fantini. 2000. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations. Virology 270:310-316.
28. Van Vaerenbergh, K., K. Van Laethem, J. Albert, C. A. Boucher, B. Clotet, M. Floridia, J. Gerstoft, B. Hejdeman, C. Nielsen, C. Pannecouque, L. Perrin, M. F. Pirillo, L. Ruiz, J. C. Schmit, F. Schneider, A. Schoolmeester, R. Schuurman, H. J. Stellbrink, L. Stuyver, J. Van Lunzen, B. Van Remoortel, E. Van Wijngaerden, S. Vella, M. Witvrouw, S. Yerly, E. De Clercq, J. Destmyer, and A. M. Vandamme. 2000. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicroh. Agents Chemother. 44:2109-2117.
29. Winters, M. A., K. I. Cooley, Y. A. Girard, D. J. Levee, H. Hamdan, R. W. Shafer, D. A. Katzenstein, and T. C. Merigan. 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Investig. 102: 1769-1775.
30. Winters, M. A., K. L. Coolley, P. Cheng, Y. A. Girard, H. Hamdan, L. C. Kovari, and T. C. Merigan. 2000. Genotypic, phenotypic, and modeling studies of a deletion in the β3-β4 region of the human immunodeficiency virus type 1 reverse transeriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. J. Virol. 74:10707-10713.
31. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to prolease inhibitors in vivo. J. Virol. 72:3300-3306.